Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19

0557229 - BFÚ 2023 RIV CH eng J - Článek v odborném periodiku
Štros, Michal - Polanská, Eva - Hlavacova, T. - Skladal, P.
Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19.
Biomolecules. Roč. 12, č. 4 (2022), č. článku 544. E-ISSN 2218-273X
Grant CEP: GA MZd(CZ) NU20-08-00106
Institucionální podpora: RVO:68081707
Klíčová slova: protein * dna * binding * forms * hmgb1 * plasma/serum * elisa * emsa * immunosensor * covid-19
Obor OECD: Biochemistry and molecular biology
Impakt faktor: 5.5, rok: 2022
Způsob publikování: Open access
https://www.mdpi.com/2218-273X/12/4/544

Extracellular HMGB1 protein is known to induce inflammatory responses leading to an inflammatory storm. The outbreak of the Severe Acute Respiratory Syndrome COVID-19 due to the SARS-CoV-2 virus has resulted in a huge health concern worldwide. Recent data revealed that plasma/serum HMGB1 levels of patients suffering from inflammation-mediated disorders-such as COVID-19, cancer, and autoimmune disorders-correlate positively with disease severity and vice versa. A late release of HMGB1 in sepsis suggests the existence of a wide therapeutic window for treating sepsis. Rapid and accurate methods for the detection of HMGB1 levels in plasma/serum are, therefore, of great importance for monitoring the occurrence, treatment success, and survival prediction of patients with inflammation-mediated diseases. In this review, we briefly explain the role of HMGB1 in the cell, and particularly the involvement of extracellular HMGB1 (released from the cells) in inflammation-mediated diseases, with an emphasis on COVID-19. The current assays to measure HMGB1 levels in human plasma-Western blotting, ELISA, EMSA, and a new approach based on electrochemical immunosensors, including some of our preliminary results-are presented and thoroughly discussed.
Trvalý link: https://hdl.handle.net/11104/0340704